{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:40:33Z","timestamp":1794343233920,"version":"4.9.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"SetPoint Medical, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41591-025-04114-7","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:02:16Z","timestamp":1766397736000},"page":"369-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial"],"prefix":"10.1038","volume":"32","author":[{"given":"John R. P.","family":"Tesser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela R.","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Jane","family":"Box","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua P.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pendleton Brewster","family":"Wickersham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4283-9683","authenticated-orcid":false,"given":"Guillermo J.","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman B.","family":"Gaylis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon K. W.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leroy A.","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Ridley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gineth Paola","family":"Pinto-Patarroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart N.","family":"Novack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin A.","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-7546","authenticated-orcid":false,"given":"Minna","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6489-5902","authenticated-orcid":false,"given":"Eric C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Pando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn R.","family":"Parris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff R.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul K.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1666-793X","authenticated-orcid":false,"given":"Victoria","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-6858","authenticated-orcid":false,"given":"Yaakov A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Derosier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2620-7387","authenticated-orcid":false,"given":"R. Mark","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2144-5454","authenticated-orcid":false,"given":"David","family":"Chernoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"4114_CR1","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo, A., Bathon, J. M. & Emery, P. Rheumatoid arthritis. Lancet 402, 2019\u20132033 (2023).","journal-title":"Lancet"},{"key":"4114_CR2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel, L. et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 73, 924\u2013939 (2021).","journal-title":"Arthritis Care Res."},{"key":"4114_CR3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00296-003-0357-5","volume":"24","author":"H Evrengul","year":"2004","unstructured":"Evrengul, H. et al. Heart rate variability in patients with rheumatoid arthritis. Rheumatol. Int. 24, 198\u2013202 (2004).","journal-title":"Rheumatol. Int."},{"key":"4114_CR4","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-025-03567-y","volume":"27","author":"MC Baker","year":"2025","unstructured":"Baker, M. C., Nagy, D., Tamang, S., Horvath-Puho, E. & Sorensen, H. T. Vagotomy and the incidence of rheumatoid arthritis and osteoarthritis: a Danish register-based study. Arthritis Res. Ther. 27, 106 (2025).","journal-title":"Arthritis Res. Ther."},{"key":"4114_CR5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ebiom.2016.02.029","volume":"6","author":"FA Koopman","year":"2016","unstructured":"Koopman, F. A. et al. Autonomic dysfunction precedes development of rheumatoid arthritis: a prospective cohort study. eBioMedicine 6, 231\u2013237 (2016).","journal-title":"eBioMedicine"},{"key":"4114_CR6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nature01321","volume":"420","author":"KJ Tracey","year":"2002","unstructured":"Tracey, K. J. The inflammatory reflex. Nature 420, 853\u2013859 (2002).","journal-title":"Nature"},{"key":"4114_CR7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nri2566","volume":"9","author":"KJ Tracey","year":"2009","unstructured":"Tracey, K. J. Reflex control of immunity. Nat. Rev. Immunol. 9, 418\u2013428 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"4114_CR8","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.immuni.2017.06.008","volume":"46","author":"SS Chavan","year":"2017","unstructured":"Chavan, S. S., Pavlov, V. A. & Tracey, K. J. Mechanisms and therapeutic relevance of neuro-immune communication. Immunity 46, 927\u2013942 (2017).","journal-title":"Immunity"},{"key":"4114_CR9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1600-065X.2012.01138.x","volume":"248","author":"PS Olofsson","year":"2012","unstructured":"Olofsson, P. S., Rosas-Ballina, M., Levine, Y. A. & Tracey, K. J. Rethinking inflammation: neural circuits in the regulation of immunity. Immunol. Rev. 248, 188\u2013204 (2012).","journal-title":"Immunol. Rev."},{"key":"4114_CR10","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1016\/j.neuron.2022.09.003","volume":"110","author":"VA Pavlov","year":"2022","unstructured":"Pavlov, V. A. & Tracey, K. J. Bioelectronic medicine: preclinical insights and clinical advances. Neuron 110, 3627\u20133644 (2022).","journal-title":"Neuron"},{"key":"4114_CR11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.immuni.2016.12.009","volume":"46","author":"J Dalli","year":"2017","unstructured":"Dalli, J., Colas, R. A., Arnardottir, H. & Serhan, C. N. Vagal regulation of group 3 innate lymphoid cells and the immunoresolvent PCTR1 controls infection resolution. Immunity 46, 92\u2013105 (2017).","journal-title":"Immunity"},{"key":"4114_CR12","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1016\/S2665-9913(20)30172-7","volume":"2","author":"MC Genovese","year":"2020","unstructured":"Genovese, M. C. et al. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. Lancet Rheumatol. 2, e527\u2013e538 (2020).","journal-title":"Lancet Rheumatol."},{"key":"4114_CR13","doi-asserted-by":"crossref","first-page":"8284","DOI":"10.1073\/pnas.1605635113","volume":"113","author":"FA Koopman","year":"2016","unstructured":"Koopman, F. A. et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 113, 8284\u20138289 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4114_CR14","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40744-025-00798-y","volume":"12","author":"NB Gaylis","year":"2025","unstructured":"Gaylis, N. B. et al. Neuroimmune modulation for drug-refractory rheumatoid arthritis: long-term safety and efficacy in patients enrolled in a pilot vagus nerve stimulation study. Rheumatol. Ther. 12, 1125\u20131136 (2025).","journal-title":"Rheumatol. Ther."},{"key":"4114_CR15","doi-asserted-by":"crossref","DOI":"10.1186\/s42234-023-00138-x","volume":"10","author":"D Peterson","year":"2024","unstructured":"Peterson, D. et al. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectron. Med. 10, 8 (2024).","journal-title":"Bioelectron. Med."},{"key":"4114_CR16","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a034330","volume":"10","author":"YA Levine","year":"2020","unstructured":"Levine, Y. A., Faltys, M. & Chernoff, D. Harnessing the inflammatory reflex for the treatment of inflammation-mediated diseases. Cold Spring Harb. Perspect. Med. 10, a034330 (2020).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"4114_CR17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson, D. T. et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727\u2013735 (1995).","journal-title":"Arthritis Rheum."},{"key":"4114_CR18","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3899\/jrheum.161433","volume":"44","author":"M Ostergaard","year":"2017","unstructured":"Ostergaard, M. et al. The OMERACT rheumatoid arthritis magnetic resonance imaging (MRI) scoring system: updated recommendations by the OMERACT MRI in arthritis working group. J. Rheumatol. 44, 1706\u20131712 (2017).","journal-title":"J. Rheumatol."},{"key":"4114_CR19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/rheumatology\/keae544","volume":"64","author":"ZLM Hofman","year":"2025","unstructured":"Hofman, Z. L. M. et al. Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?. Rheumatology (Oxford) 64, 65\u201373 (2025).","journal-title":"Rheumatology (Oxford)"},{"key":"4114_CR20","volume":"16","author":"J Kay","year":"2014","unstructured":"Kay, J. et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res. Ther. 16, R40 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"4114_CR21","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese, M. C. et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391, 2513\u20132524 (2018).","journal-title":"Lancet"},{"key":"4114_CR22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester, G. R. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 451\u2013460 (2013).","journal-title":"Lancet"},{"key":"4114_CR23","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor \u03b1 inhibition. N. Engl. J. Med. 353, 1114\u20131123 (2005).","journal-title":"N. Engl. J. Med."},{"key":"4114_CR24","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese, M. C. et al. Baricitinib in patients with refractory rheumatoid arthritis. N. Engl. J. Med. 374, 1243\u20131252 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4114_CR25","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3899\/jrheum.131088","volume":"41","author":"F Gandjbakhch","year":"2014","unstructured":"Gandjbakhch, F. et al. Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a followup MRI study of 254 patients in clinical remission or low disease activity. J. Rheumatol. 41, 398\u2013406 (2014).","journal-title":"J. Rheumatol."},{"key":"4114_CR26","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-2000-1","volume":"21","author":"PG Conaghan","year":"2019","unstructured":"Conaghan, P. G. et al. Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis. Arthritis Res. Ther. 21, 214 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"4114_CR27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","volume":"8","author":"G Schett","year":"2012","unstructured":"Schett, G. & Gravallese, E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat. Rev. Rheumatol. 8, 656\u2013664 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"4114_CR28","doi-asserted-by":"crossref","first-page":"15455","DOI":"10.1073\/pnas.1206061109","volume":"109","author":"A Bajayo","year":"2012","unstructured":"Bajayo, A. et al. Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual. Proc. Natl Acad. Sci. USA 109, 15455\u201315460 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4114_CR29","first-page":"255","volume":"21","author":"A Tamimi","year":"2021","unstructured":"Tamimi, A. et al. Could vagus nerve stimulation influence bone remodeling?. J. Musculoskelet. Neuronal Interact. 21, 255\u2013262 (2021).","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"4114_CR30","volume":"9","author":"YA Levine","year":"2014","unstructured":"Levine, Y. A. et al. Neurostimulation of the cholinergic anti-inflammatory pathway ameliorates disease in rat collagen-induced arthritis. PLoS ONE 9, e104530 (2014).","journal-title":"PLoS ONE"},{"key":"4114_CR31","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1152\/physrev.00014.2017","volume":"98","author":"F Elefteriou","year":"2018","unstructured":"Elefteriou, F. Impact of the autonomic nervous system on the skeleton. Physiol. Rev. 98, 1083\u20131112 (2018).","journal-title":"Physiol. Rev."},{"key":"4114_CR32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/joim.12871","volume":"286","author":"CN Serhan","year":"2019","unstructured":"Serhan, C. N., de la Rosa, X. & Jouvene, C. Novel mediators and mechanisms in the resolution of infectious inflammation: evidence for vagus regulation. J. Intern. Med. 286, 240\u2013258 (2019).","journal-title":"J. Intern. Med."},{"key":"4114_CR33","volume":"129","author":"M Ali","year":"2021","unstructured":"Ali, M., Yang, F., Plachokova, A. S., Jansen, J. A. & Walboomers, X. F. Application of specialized pro-resolving mediators in periodontitis and peri-implantitis: a review. Eur. J. Oral. Sci. 129, e12759 (2021).","journal-title":"Eur. J. Oral. Sci."},{"key":"4114_CR34","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bbi.2017.04.003","volume":"64","author":"GS Bassi","year":"2017","unstructured":"Bassi, G. S. et al. Modulation of experimental arthritis by vagal sensory and central brain stimulation. Brain Behav. Immun. 64, 330\u2013343 (2017).","journal-title":"Brain Behav. Immun."},{"key":"4114_CR35","doi-asserted-by":"crossref","first-page":"C365","DOI":"10.1152\/ajpcell.00039.2023","volume":"325","author":"G Rosch","year":"2023","unstructured":"Rosch, G., Zaucke, F. & Jenei-Lanzl, Z. Autonomic nervous regulation of cellular processes during subchondral bone remodeling in osteoarthritis. Am. J. Physiol. Cell Physiol. 325, C365\u2013C384 (2023).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"4114_CR36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/ard-2022-223762","volume":"82","author":"T Frisell","year":"2023","unstructured":"Frisell, T. et al. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Ann. Rheum. Dis. 82, 601\u2013610 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"4114_CR37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.seizure.2020.09.027","volume":"83","author":"DH Toffa","year":"2020","unstructured":"Toffa, D. H., Touma, L., El Meskine, T., Bouthillier, A. & Nguyen, D. K. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: a critical review. Seizure 83, 104\u2013123 (2020).","journal-title":"Seizure"},{"key":"4114_CR38","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/art.42637","volume":"75","author":"MC Baker","year":"2023","unstructured":"Baker, M. C. et al. A randomized, double-blind, sham-controlled, clinical trial of auricular vagus nerve stimulation for the treatment of active rheumatoid arthritis. Arthritis Rheumatol. 75, 2107\u20132115 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"4114_CR39","unstructured":"Center for Biologics Evaluation and Research, Center for Devices and Radiological Health & Center for Drug Evaluation and Research. Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA). www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-development-programs-drugs-devices-and-biological-products-treatment-rheumatoid-arthritis (1999)."},{"key":"4114_CR40","unstructured":"Center for Biologics Evaluation and Research, Center for Devices and Radiological Health & Center for Drug Evaluation and Research. Rheumatoid Arthritis: Developing Drug Products for Treatment. Docket Number FDA-2013-D-0571. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rheumatoid-arthritis-developing-drug-products-treatment (2013)."},{"key":"4114_CR41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/17407745241276124","volume":"21","author":"J Munoz Laguna","year":"2024","unstructured":"Munoz Laguna, J., Lee, H., Poltavskiy, E., Kim, J. & Bang, H. Participant\u2019s treatment guesses and adverse events in back pain trials: Nocebo in action?. Clin. Trials 21, 759\u2013762 (2024).","journal-title":"Clin. Trials"},{"key":"4114_CR42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/10601331003777444","volume":"27","author":"H Bang","year":"2010","unstructured":"Bang, H., Flaherty, S. P., Kolahi, J. & Park, J. Blinding assessment in clinical trials: a review of statistical methods and a proposal of blinding assessment protocol. Clin. Res. Regul. Aff. 27, 42\u201351 (2010).","journal-title":"Clin. Res. Regul. Aff."},{"key":"4114_CR43","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/ecco-jcc\/jjad151","volume":"17","author":"G D'Haens","year":"2023","unstructured":"D'Haens, G. et al. Neuroimmune modulation through vagus nerve stimulation reduces inflammatory activity in Crohn\u2019s disease patients: a prospective open-label study. J. Crohns Colitis 17, 1897\u20131909 (2023).","journal-title":"J. Crohns Colitis"},{"key":"4114_CR44","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2014-206934","volume":"75","author":"JF Baker","year":"2016","unstructured":"Baker, J. F., Conaghan, P. G., Emery, P., Baker, D. G. & Ostergaard, M. Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis. Ann. Rheum. Dis. 75, 1114\u20131119 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"4114_CR45","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","volume":"75","author":"Y Hochberg","year":"1988","unstructured":"Hochberg, Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75, 800\u2013802 (1988).","journal-title":"Biometrika"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04114-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04114-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04114-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:02:51Z","timestamp":1769007771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04114-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4114"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04114-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.R.P.T. reports consulting, grant\/research support and\/or honoraria (including speakers bureau, symposia and expert witness) from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Gilead, GlaxoSmithKline, IGM Biosciences, Janssen, Merck, Novartis, Pfizer, Roche and UCB; and consulting from SetPoint Medical. E.J.B. reports grant\/research support from SetPoint Medical. J.P.J. reports consultancy and grant\/research support from Janssen and SetPoint Medical. P.B.W. reports consulting, advisory roles, speaker honoraria and\/or grant\/research support from AbbVie, Amgen, AstraZeneca, Eli Lilly, Janssen, Novartis and UCB. G.J.V. reports advisory, consultancy, grant\/research support and\/or speaker honoraria from AbbVie, Alexion, Amgen, Artiva Biotherapeutics, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Eli Lilly, Esaote, Exagen, Genentech, Gilead, Global Healthy Living Foundation, Horizon, Image Analysis Group, Janssen, Mallinckrodt, Merck, Novartis, Pfizer, Pharmacia, Radius, Regeneron, Sandoz, Sanofi, Takeda, Theramex, UCB and Vividion Therapeutics. N.B.G. reports research funding from AbbVie, Acelyrn, Alumis, Amgen, Aqtual, Artiva, Biogen, Bristol Myers Squibb, Eli Lilly, Galapagos, Genentech, Gilead, GlaxoSmithKline, Horizon, IGM Biosciences, Moonlake, Novartis, Sanofi, SetPoint Medical, Takeda and UCB; is an officer\/board member of AB Solutions; and an advisor\/review panel member for Inmedix. G.K.W.L. reports advisory roles, consultancy, speaker honoraria and\/or research support from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, SetPoint Medical and UCB. L.A.P. reports research funding from AbbVie, Amgen, Eli Lilly, Horizon, Janssen, SetPoint Medical and UCB. D.J.R. reports research funding from Bristol Myers Squibb, Eli Lilly, Johnson & Johnson and UCB. M.K. reports research funding from Janssen, Novartis and SetPoint Medical; membership on advisory boards for Janssen and Novartis; and royalties from Springer Publications. J.R.P. reports consulting, advisory roles, research funding, intellectual property\/patents and\/or speaker honoraria from Amgen, Arthrosi, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Novartis, SOBI and UCB. T.S. reports consulting, research funding and\/or stock options from AbbVie, Amgen, Johnson & Johnson, Merck, Novartis, Takeda and UCB. V.V. reports research funding from AstraZeneca, Scipher Medicine and SetPoint Medical. Y.A.L. and D.C. are employees of and hold equity\/stock options and intellectual property\/patents in SetPoint Medical. M.L.E. and A.A.D. are employees of and hold equity\/stock options in SetPoint Medical. J.R.C. reports consulting and\/or research funding from AbbVie, Amgen, Bendcare, Bristol Myers Squibb, Corrona, Crescendo, Eli Lilly, Genentech, GlaxoSmithKline, Janssen, Moderna, Novartis, Pfizer, Roche, Sanofi and UCB; and is an officer\/board member of FASTER. R.M.R. reports consulting and\/or research funding from Neuropace, Medtronic, Inbrain and SetPoint Medical. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}